MetaCap

Citius Oncology (CTOR) vs Tenax Therapeutics (TENX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Citius Oncology (CTOR) has outperformed Tenax Therapeutics (TENX) over the past year, losing 55.4% versus a loss of 84.7%. Tenax Therapeutics is the larger company by market cap ($56.9 million vs $53.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTOR-55.44%TENX-84.66%
+135%+20%-95%
Nov 21, 20251 yearNov 20, 2026
CTOR-95.01%TENX-99.42%
+321%+101%-119%
Dec 5, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTOR versus TENX key metrics
MetricCTORTENX
Share price$0.5035$1.25
Market cap$53.25M$56.92M
1-day change-10.95%-10.07%
YTD return-49.65%-89.75%
1-year return-55.44%-84.66%
5-year return—-99.94%
EPS (TTM)$-0.48$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-24.76M$-52.60M
52-week high$1.83$19.40
52-week low$0.491$1.24
Distance from 52-week high-72.49%-93.56%
Analyst consensusnonenone
Avg. price target upside+694.44%+904.80%
Average volume114.02K3.15M
Shares outstanding105.76M45.54M
Employees—14
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTOR has outperformed TENX by 29.2 percentage points over the past year.

About Citius Oncology

CTOR stock →

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.

Health Care · Biotechnology: Pharmaceutical Preparations

About Tenax Therapeutics

TENX stock →

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

CTOR vs TENX FAQ

Which is bigger, Citius Oncology or Tenax Therapeutics?

Tenax Therapeutics (TENX) is larger, with a market capitalization of $56.92M compared with $53.25M for Citius Oncology (CTOR).

Which stock has performed better over the past year, CTOR or TENX?

CTOR returned -55.44% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.

Are Citius Oncology and Tenax Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons